$GNLX News

Benchmark Maintains Speculative Buy on Genelux, Lowers Price Target to $20

Genelux Q4 EPS $(0.24) Misses $(0.21) Estimate

Genelux Corporation to Participate in Upcoming Conferences

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

Genelux shares are trading lower. The company announced the pricing of a public offering of 6.67 million common shares at a price of $3.00 per share.

Genelux shares are trading lower. The company announced the pricing of a public offering of 6.67 million common shares at a price of $3.00 per share.

Genelux Prices ~$20M Public Offering Of 6.67M Shares At A Price Of $3/Share

Genelux Corporation Announces Proposed Public Offering of Common Stock

Genelux Corporation Announces Proposed Public Offering Of Common Stock; No Terms Disclosed

Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials

Genelux Announces Interim Results From Two Ongoing Trials, Phase 1b/2 SCLC And Phase 2 VIRO-25, Evaluating Systemic Administration Of Olvi-Vec In Patients With Progressive SCLC And NSCLC

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference

Institutions along with retail investors who hold considerable shares inGenelux Corporation (NASDAQ:GNLX) come under pressure; lose 16% of holdings value

Genelux: An Oncolytic Virus Player About To Cross The Phase 3 Finish Line, But On Shaky Ground

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Genelux Q3 EPS $(0.21), Inline

Lake Street Initiates Coverage On Genelux with Buy Rating, Announces Price Target of $16

Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth?